2. Grumbach MM. The neuroendocrinology of human puberty revisited. Horm Res 2002;57 Suppl 2:2–14.
3. Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med 2012;366:443–53.
10. Spaziani M, Tarantino C, Tahani N, Gianfrilli D, Sbardella E, Lenzi A, et al. Hypothalamo-pituitary axis and puberty. Mol Cell Endocrinol 2021;520:111094.
13. Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology 2014;2:794–808.
14. Prior M, Stewart J, McEleny K, Dwyer AA, Quinton R. Fertility induction in hypogonadotropic hypogonadal men. Clin Endocrinol (Oxf) 2018;89:712–8.
15. Walker WH, Cheng J. FSH and testosterone signaling in Sertoli cells. Reproduction 2005;130:15–28.
16. Zacharin M. Pubertal induction in hypogonadism: current approaches including use of gonadotrophins. Best Pract Res Clin Endocrinol Metab 2015;29:367–83.
17. Lenzi A, Balercia G, Bellastella A, Colao A, Fabbri A, Foresta C, et al. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest 2009;32:934–8.
18. Young J, Xu C, Papadakis GE, Acierno JS, Maione L, Hietamäki J, et al. Clinical management of congenital hypogonadotropic hypogonadism. Endocr Rev 2019;40:669–710.
19. Palmert MR, Hirschhorn JN. Genetic approaches to stature, pubertal timing, and other complex traits. Mol Genet Metab 2003;80:1–10.
20. Stamou MI, Varnavas P, Kentrou M, Adamidou F, Voutetakis A, Jing J, et al. Isolated GNRH deficiency: genotypic and phenotypic characteristics of the genetically heterogeneous Greek population. Eur J Endocrinol 2017;176:L1–5.
21. Gach A, Pinkier I, Sałacińska K, Szarras-Czapnik M, Salachna D, Kucińska A, et al. Identification of gene variants in a cohort of hypogonadotropic hypogonadism: Diagnostic utility of custom NGS panel and WES in unravelling genetic complexity of the disease. Mol Cell Endocrinol 2020;517:110968.
25. Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism 2018;86:124–34.
26. Topaloglu AK, Kotan LD. Genetics of hypogonadotropic hypogonadism. Endocr Dev 2016;29:36–49.
29. Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andrè V, Marzagalli M, et al. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update 2016;22:358–81.
30. Pitteloud N, Durrani S, Raivio T, Sykiotis GP. Complex genetics in idiopathic hypogonadotropic hypogonadism. Front Horm Res 2010;39:142–53.
31. Main KM, Schmidt IM, Toppari J, Skakkebaek NE. Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH. Eur J Endocrinol 2002;146:75–9.
32. Bougnères P, François M, Pantalone L, Rodrigue D, Bouvattier C, Demesteere E, et al. Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. J Clin Endocrinol Metab 2008;93:2202–5.
33. Stoupa A, Samara-Boustani D, Flechtner I, Pinto G, Jourdon I, González-Briceño L, et al. Efficacy and safety of continuous subcutaneous infusion of recombinant human gonadotropins for congenital micropenis during early infancy. Horm Res Paediatr 2017;87:103–10.
34. Jayasena CN, Anderson RA, Llahana S, Barth JH, MacKenzie F, Wilkes S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf) 2022;96:200–19.
35. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103:1715–44.
36. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human folliclestimulating hormone and human chorionic gonadotropin. Fertil Steril 2009;92:594–604.
37. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 2009;94:801–8.
38. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol 2005;173:2072–5.
39. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002;87:4128–36.
40. Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988;66:1144–51.
41. Delemarre-Van de Waal HA, Odink RJ. Pulsatile GnRH treatment in boys and girls with idiopathic hypogonadotrophic hypogonadism. Hum Reprod 1993;8 Suppl 2:180–3.
42. Delemarre-Van de Waal HA. Induction of testicular growth and spermatogenesis by pulsatile, intravenous administration of gonadotrophin-releasing hormone in patients with hypogonadotrophic hypogonadism. Clin Endocrinol (Oxf) 1993;38:473–80.
43. Hoffman AR, Crowley WF Jr. Induction of puberty in men by long-term pulsatile administration of lowdose gonadotropin-releasing hormone. N Engl J Med 1982;307:1237–41.
44. Wei C, Long G, Zhang Y, Wang T, Wang S, Liu J, et al. Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile gonadotropin-releasing hormone therapy versus gonadotropin therapy: a systematic review and meta-analysis. World J Mens Health 2021;39:654–65.
46. Dwyer AA, Raivio T, Pitteloud N. Gonadotrophin replacement for induction of fertility in hypogonadal men. Best Pract Res Clin Endocrinol Metab 2015;29:91–103.
47. Anderson RC, Newton CL, Anderson RA, Millar RP. Gonadotropins and their analogs: current and potential clinical applications. Endocr Rev 2018;39:911–37.
48. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol (Oxf) 2010;72:731–7.
49. Casarini L, Crépieux P, Reiter E, Lazzaretti C, Paradiso E, Rochira V, et al. FSH for the treatment of male infertility. Int J Mol Sci 2020;21.